Nasdaq Bid-Price Deficiency Notice Hits Sub-$0.11 Microcap
BDMD sits 43% above its 52-week low of $0.073.
Summary
Baird Medical received a Nasdaq minimum bid price deficiency notice, and the stock fell on the disclosure. The shares trade around $0.10, so the company now has the standard 180-day window to regain a $1.00 closing bid or face delisting proceedings. This lands on top of an already strained capital structure: a $3.7 million convertible note in September with investor-favorable terms, a $4.35 million senior secured convertible note with a 92% VWAP conversion discount, and a going-concern assessment resolved only through a $2.0 million support letter from its CEO. A sub-$1 stock with heavy dilution overhang makes a reverse split the likely remedy, which would reset the share count again. The clock is now running on compliance; watch for a reverse-split announcement or a Nasdaq extension request.
At the time of this announcement, BDMD was trading at $0.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $0.07 to $3.70. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.